Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Fig. 3

Relative change in (a) SP-A, (b) SP-D, and (c) KL-6 levels in the initial 3 and 6 months. Changes in serum SP-A at 3 and 6 months, SP-D at 6 months, and KL-6 at 3 and 6 months were significantly smaller in the stable group than the progression group (*p < 0.05). Data were analyzed by Mann–Whitney U test. Horizontal line indicates median concentration. The upper and lower limits of the box indicate the inter quartile range

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us